Valérie Boige - Concepedia

Author

Valérie Boige

Also Known As

Christophe Desterke, Church, David, Frédéric Bibeau, Karine Le Malicot, M. Ducreux, Service de cancérologie, Hôpital Paul Brousse, N. Boige, The FREGAT Working Group, V Boige, V. Boige, VALÉRIE BOIGE

508

Publications

36.1K

Citations

H-Index

104

Concepts

All Affiliations

Institut Gustave Roussy Inserm Université Paris Cité Assistance Publique – Hôpitaux de Paris Centre Antoine Lacassagne

About

Valérie Boige is an author at Institut Gustave Roussy specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	47	90	13.8K
2	Health Sciences	23	30	3.3K
3	Engineering	1	1	36
4	Public Health	1	1	26
5	Biochemistry	1	1	213

Valérie Boige

165

Publications

32.3K

Citations

H-Index

Page 1

	Year	Citations
The consensus molecular subtypes of colorectal cancer Justin Guinney, Rodrigo Dienstmann, Xin Wang, Nature Medicine MedicinePathologyColorectal CancerCancer GenomicsOncology	2015	5K
<i>KRAS</i> Mutation Status Is Predictive of Response to Cetuximab Therapy in Colorectal Cancer Astrid Lièvre, Jean‐Baptiste Bachet, Delphine Le Corre, Cancer Research	2006	2.2K
Perioperative Chemotherapy Compared With Surgery Alone for Resectable Gastroesophageal Adenocarcinoma: An FNCLCC and FFCD Multicenter Phase III Trial Marc Ychou, Valérie Boige, Jean‐Pierre Pignon, Journal of Clinical Oncology	2011	2.1K
Gene Expression Classification of Colon Cancer into Molecular Subtypes: Characterization, Validation, and Prognostic Value Laëtitia Marisa, Aurélien de Reyniès, Alex Duval, PLoS Medicine	2013	1.5K
<i>KRAS</i> Mutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With Cetuximab Astrid Lièvre, Jean‐Baptiste Bachet, Valérie Boige, Journal of Clinical Oncology	2008	1.4K
Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial Thierry Conroy, Jean-François Bosset, Pierre-Luc Etienne, The Lancet Oncology	2021	1.2K
Immunogenic death of colon cancer cells treated with oxaliplatin Antoine Tesnière, F. Schlemmer, Valérie Boige, Oncogene Tumor BiologyMedicineColon Cancer CellsColorectal CancerCancer Treatment	2009	1.1K
Analysis of <i>PTEN</i> , <i>BRAF</i> , and <i>EGFR</i> Status in Determining Benefit From Cetuximab Therapy in Wild-Type <i>KRAS</i> Metastatic Colon Cancer Pierre Laurent‐Puig, Anne Cayre, Gilles Manceau, Journal of Clinical Oncology	2009	665
Surgery Alone Versus Chemoradiotherapy Followed by Surgery for Stage I and II Esophageal Cancer: Final Analysis of Randomized Controlled Phase III Trial FFCD 9901 C. Mariette, Laëtitia Dahan, F. Mornex, Journal of Clinical Oncology	2014	597
Brivanib in Patients With Advanced Hepatocellular Carcinoma Who Were Intolerant to Sorafenib or for Whom Sorafenib Failed: Results From the Randomized Phase III BRISK-PS Study Josep M. Llovet, Thomas Decaens, Jean‐Luc Raoul, Journal of Clinical Oncology	2013	592

Page 1